Nathalie Jetté, MD, MSc, FRCPC, CSCN(EEG), FAAN, FAES, FANA, Guest Editor
Professor of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York

*Relationship Disclosure: Dr Jetté has received personal compensation in the range of $500 to $4999 for serving as an Associate Editor for Epilepsia. The institution of Dr Jette has received research support from the American Epilepsy Society, the National Institutes of Health, the NORSE Institute and the Patient-Centered Outcomes Research Institute.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Jetté reports no disclosure.

Bassel W. Abou-Khalil, MD, FAAN

Professor of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee

*Relationship Disclosure: Dr Abou-Khalil has served on the editorial board of Clinical Neurophysiology. The institution of Dr Abou-Khalil has received research support from Biogen, Cerevel Therapeutics, Human Epilepsy Project, Otsuka America Pharmaceutical, Inc, SK-Pharma, Sunovion Pharmaceuticals Inc, UCB SA, and Xenon.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Abou-Khalil discusses the unlabeled/investigational use of cannabidiol and clobazam for the treatment of focal-onset seizures, gabapentin for the treatment of headache and sleep disorders, lamotrigine as a first-line treatment for epilepsy, perampanel for myoclonus, primidone for the treatment of essential tremor, valproate for the treatment of generalized myoclonic and generalized tonic-clonic seizures, and zonisamide as initial monotherapy for epilepsy.

Francesco Brigo, MD

Department of Neurology, Hospital of Merano, Merano-Meran, Italy

*Relationship Disclosure: Dr Brigo reports no disclosure.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Brigo reports no disclosure.

Jeffrey Britton, MD, FAAN

Chair, Division of Epilepsy; Professor of Neurology, Mayo Clinic, Rochester, Minnesota

**Relationship Disclosure: Dr Britton has received personal compensation in the range of $0 to $499 for serving as an online course instructor for the American Clinical Neurophysiology Society.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Britton discusses the unlabeled/investigational use of azathioprine, cyclophosphamide, IVIg, methylprednisolone, mycophenolate mofetil, prednisone, and rituximab for the treatment of autoimmune encephalitis.

Esther Bui, MD, FRCP(C)

Assistant Professor of Neurology, University of Toronto; Epilepsy Fellowship Director; Women’s Neurology Fellowship Director; Director of Education–Canadian League Against Epilepsy, Toronto, Ontario, Canada

*Relationship Disclosure: Dr Bui reports no disclosure.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Bui discusses the unlabeled/investigational use of acetazolamide, clobazam, and hormonal therapies for the treatment of catamenial epilepsy.

Honor Coleman, MPsych, PhD

Clinical Neuropsychologist, Alfred Health; Lecturer, University of Melbourne, Melbourne, Victoria, Australia

*Relationship Disclosure: Relationship Disclosure: Dr Coleman has received personal compensation for serving as a research lead for the Epilepsy Foundation of Australia.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Coleman reports no disclosure.

Judith Helen Cross, MBChB, PhD

Developmental Neurosciences, University College London Great Ormond Street Institute of Child Health; Department of Neurology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

*Relationship Disclosure: Dr Cross holds an endowed chair at the University College London Great Ormond Street Institute of Child Health. The institution of Dr Cross has received support from Biocodex, the Engineering and Physical Sciences Research Council, Epilepsy Research UK, Great Ormond Street Hospital Charity, GW Pharmaceuticals plc, Marinius Pharmaceuticals, Inc, the National Institute of Health Research Great Ormond Street Hospital Biomedical Research Centre, Nutricia, Vitafl o (International) Limited, the Waterloo Foundation, and Zogenix.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Cross discusses the unlabeled/investigational use of memantine for the treatment of GRIN2A-related epilepsies, quinidine for the treatment of KCNT1-related epilepsies, and radiprodil for the treatment of GRIN2B-related epilepsies.

George W. Culler IV, MD

Assistant Professor of Neurology, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire

*Relationship Disclosure: Dr Culler reports no disclosure.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Culler discusses the unlabeled/investigational use of neurostimulation for the treatment of refractory genetic/idiopathic generalized epilepsy.

Lisa Gillinder, MBBS, FRACP

Service Director, Mater Advanced Epilepsy Unit, Mater Hospital, South Brisbane, Queensland, Australia

*Relationship Disclosure: Dr Gillinder reports no disclosure.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Gillinder discusses the unlabeled/investigational use of azathioprine, cyclophosphamide, IVIg, methylprednisolone, mycophenolate mofetil, prednisone, and rituximab for the treatment of autoimmune encephalitis.

Maria Gogou, MD, PhD

Department of Neurology, Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London, United Kingdom

*Relationship Disclosure: Dr Gogou reports no disclosure.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Gogou discusses the unlabeled/investigational use of memantine for the treatment of GRIN2A-related epilepsies, quinidine for the treatment of KCNT1-related epilepsies, and radiprodil for the treatment of GRIN2B-related epilepsies.

Barbara C. Jobst, MD, Dr Med, FAAN

Chair and Professor of Neurology, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire

*Relationship Disclosure: Dr Jobst has received personal compensation of $20,000 for serving as an Associate Editor on Neurology. The institution of Dr Jobst has received research support from the American Epilepsy Society, the Centers for Disease Control and Prevention, the Department of Defense, the Epilepsy Foundation, Harvard Pilgrim Health Care, Inc, the National Institutes of Health, and NeuroPace, Inc.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Jobst discusses the unlabeled/investigational use of neurostimulation for the treatment of refractory genetic/idiopathic generalized epilepsy.

Markus Leitinger, MD, MSc

Privatdozent, Department of Neurology, Neurointensive Care, and Neurorehabilitation, Christian Doppler University Hospital, Paracelsus Medical University, Centre for Cognitive Neuroscience; Neuroscience Institute, Christian Doppler University Hospital Salzburg, Centre for Cognitive Neuroscience, Salzburg

*Relationship Disclosure: Dr Leitinger reports no disclosure.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Leitinger discusses the unlabeled/investigational use of antiseizure medications for the treatment of status epilepticus.

Anthony Marson, MBChB, MD, FRCP

Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom

*Relationship Disclosure: Dr Marson has received publishing royalties from Oxford University Press.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Marson reports no disclosure.

Marco Mula, MD, PhD, FRCP, FEAN

Consultant in Neurology and Epileptology, Atkinson Morley Regional Neuroscience Centre, St George’s University Hospital; Reader in Neurology, Institute of Medical and Biomedical Education, St George’s University of London, London, United Kingdom

*Relationship Disclosure: Dr Mula has received personal compensation in the range of $500 to $4999 for serving on a speakers bureau for Eisai Co, Ltd, and UCB, Inc, and for serving as an Associate Editor for Epilepsy & Behavior; has received publishing royalties from Elsevier and Springer Publishing Company; and has a compensated relationship with the Korean League Against Epilepsy and the Philippine League Against Epilepsy.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Mula reports no disclosure.

Kenneth A. Myers, MD, PhD, FRCPC, CSCN(EEG)

Assistant Professor, Department of Pediatrics, Division of Child Neurology, McGill University; Junior Scientist, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada

*Relationship Disclosure: Dr Myers has received personal compensation in the range of $500 to $4999 for serving as an academic writer with Springer Publishing Company. The institution of Dr Myers has received research support from Dravet Canada, Fonds de recherche du Québec, Koolen-de Vries Syndrome Foundation, The Liam Foundation, and the Savoy Foundation.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Myers discusses the unlabeled/investigational use of clobazam for the treatment of forms of epilepsy other than Lennox-Gastaut syndrome and quinidine for the treatment of epilepsy due to KCNT1 pathogenic variants.

Dang K. Nguyen, MD, PhD, FRCPC

Neurologist, Centre hospitalier de l’Université de Montréal; Professor (Neuroscience), Université de Montréal, Montreal, Quebec, Canada

*Relationship Disclosure: Dr Nguyen reports no disclosure.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Nguyen reports no disclosure.

William O. Tatum IV, DO, FAAN, FACNS, FAES

Professor of Neurology, Mayo Clinic College of Medicine & Science; Chief, Division of Epilepsy, Mayo Clinic, Jacksonville, Florida

*Relationship Disclosure: Dr Tatum has received personal compensation in the range of $500 to $4999 for serving as an Editor-in-Chief for Epilepsy & Behavior Reports and as an expert witness for a defense law firm on behalf of a patient with epilepsy with funds donated to the Epilepsy Foundation of America; has received personal compensation in the range of $10,000 to $49,999 for serving as a consultant for BioSerenity, Holberg EEG AS, Neurelis, Inc, Zimmer Biomet; and has received publishing royalties from Demos and Springer Publishers. The institution of Dr Tatum has received research support from Cerevel Therapeutics, Engage Pharma, Esai Inc, LivaNova PLC, the Mayo Clinic, Medtronic, and Xenon.
**Unlabeled Use of Products/Investigational Use Disclosure: Dr Tatum reports no disclosure.

Eugen Trinka, MD, MSc, FRCP

Professor, Department of Neurology, Neurointensive Care, and Neurorehabilitation, Christian Doppler University Hospital, Paracelsus Medical University, Centre for Cognitive Neuroscience, Salzburg; Neuroscience Institute, Christian

*Relationship Disclosure:
**Unlabeled Use of Products/Investigational Use Disclosure: